Underreporting is one of the most significant challenges in pharmacovigilance worldwide. Here is a detailed description covering what it is, its causes, how to fix it, and relevant examples.
1. What is Underreporting in Pharmacovigilance?
Underreporting refers to the widespread failure to report Adverse Drug Reactions (ADRs) and Medication Errors to the national pharmacovigilance center or the relevant regulatory authority. It means that only a small fraction of the actual incidents that occur are ever officially recorded and analyzed.
- The “Iceberg Phenomenon”: This is a common analogy. The few reported cases represent the “tip of the iceberg” visible above the water, while a vast number of unreported cases remain hidden beneath the surface, obscuring the true risk profile of a medicine.
2. Causes of Underreporting
The causes are multifaceted and involve factors from healthcare professionals, patients, and the system itself.
A. Healthcare Professional (HCP) Related Causes:
- Lack of Time / Workload: The most common barrier. Filling out complex reporting forms is seen as a low priority in a busy clinical setting.
- Complacency: The belief that only “serious” or “unexpected” reactions need to be reported. Many HCPs fail to report well-known, “common” side effects, which is crucial for understanding a drug’s real-world safety profile.
- Lack of Knowledge / Training: Uncertainty about what constitutes a reportable event, how to report it, and where to send the report.
- Diffusion of Responsibility: The assumption that “someone else” will report it (e.g., the pharmacist, another doctor, or the hospital’s safety officer).
- Fear of Litigation or Appearing Incompetent: Concerns that reporting an ADR might expose a medication error or a lapse in judgment.
- Uncertainty about Causality: Hesitation to report if the HCP is not 100% sure that the drug caused the reaction. The rule is “if in doubt, report,” but this is often misunderstood.
B.Patient-Related Causes (Why Patients Don’t Report)
- Lack of Awareness: Many patients do not know that:
- A new symptom could be a side effect of their medicine.
- There is an official system to report such side effects.
- They are allowed to report directly without going through a doctor.
- Misattribution of Symptoms: Patients often assume their new symptom is:
- A progression of their underlying disease (“My arthritis is just getting worse”).
- A new, unrelated illness (“I must be coming down with a bug”).
- A normal part of aging.
- The “Doctor Knows Best” Mindset: A belief that:
- The doctor is already aware of all possible side effects.
- It’s not their place to question or report.
- If the side effect was important, the doctor would have mentioned it.
- Fear and Concerns:
- Fear of bothering the doctor with “trivial” matters.
- Concern that reporting might lead to their medication being stopped, leaving them without treatment.
- Worry about being perceived as a “difficult” patient.
- Practical Barriers:
- Complexity: Official reporting forms can be long, technical, and confusing for a layperson.
- Lack of Accessibility: Not knowing where to find the reporting form or website.
- Time and Effort: Filling out a report is seen as time-consuming with no immediate personal benefit.
C. System-Related Causes:
- Complex and Cumbersome Reporting Systems: Lengthy, confusing forms with too many fields act as a major deterrent.
- Lack of Feedback: HCPs rarely receive any follow-up or see the impact of their reports. Without this feedback loop, reporting feels like a “black hole” and is demotivating.
- Absence of Integration: Reporting systems are often separate from the primary clinical workflow (e.g., Electronic Health Records). Having to log into a different system is a significant barrier.
- Lack of a Strong Reporting Culture: In many institutions, pharmacovigilance is not prioritized or encouraged by management.
- Inadequate Resources in LMICs: National pharmacovigilance centers in low- and middle-income countries may lack the funding, staff, or infrastructure to effectively collect and process reports.
3. How to Fix Underreporting: Potential Solutions
Addressing underreporting requires a multi-pronged approach.
A. For Healthcare Professionals:
- Simplification: Implement streamlined, user-friendly reporting forms. Your hackathon idea of a voice-first app is a perfect example of this solution.
- Education and Training: Continuous education on the importance of PV, what to report (especially the importance of reporting all reactions, not just serious ones), and how to report.
- Integration into Workflow: Embed reporting tools directly into Electronic Health Records (EHRs) and clinical software so it becomes a natural part of the patient care process.
B. For Patients
- Public Awareness Campaigns: Use simple language in pharmacies, on TV, and social media to educate patients about side effects and how to report them. Slogans like: “Noticed a side effect? Report it. You’re not just a patient, you’re a partner in safety.”
- Simplify Direct Patient Reporting:
- Develop user-friendly mobile apps and websites with simple questions.
- Your hackathon idea could be extended to have a patient-facing version where they can also report using their voice.
- Empower Patients at the Point of Care:
- Pharmacists can play a key role by asking “Have you experienced any new symptoms since starting this medication?” when dispensing drugs.
- Provide a simple, pre-paid postcard or a QR code linking to a reporting form with every prescription.
- Demonstrate Value: Show patients how their reports make a difference. Publicize examples where patient reports led to a drug’s safety information being updated.
C. Technological Solutions:
- Automated Signal Detection: Use AI and data mining to proactively detect potential ADRs from EHRs, laboratory data, and patient forums, reducing the reliance on spontaneous reporting alone.
- Mobile Health (mHealth) Applications: Develop easy-to-use apps for HCPs and direct patient reporting (see examples below).
- Natural Language Processing (NLP): Use AI to scan clinical notes and discharge summaries within EHRs to automatically identify and extract potential ADR mentions.
D. System and Cultural Changes:
- Provide Regular and Meaningful Feedback: Send newsletters, alerts, or annual summaries to reporters to show them how their data is being used to improve patient safety.
- Establish a Strong Safety Culture: Hospital and clinic management must actively promote and incentivize reporting.
- Implement Direct Patient Reporting: Empower patients to report their own experiences, bypassing potential HCP barriers.
- Legal and Regulatory Frameworks: Strengthen regulations that mandate reporting, especially for serious events, while ensuring a non-punitive environment for HCPs.
4. Real-World Examples
Example 1: The Rofecoxib (Vioxx) Case
- The Problem: The painkiller Vioxx was linked to an increased risk of heart attacks and strokes. Evidence later showed that signals of this risk were present for years before the drug was withdrawn.
- Role of Underreporting: Widespread underreporting of cardiovascular events by physicians delayed the identification of this serious safety issue, potentially exposing millions of patients to harm. It is a classic case of how underreporting can have fatal consequences.
Example 2: Direct Patient Reporting (The “Yellow Card Scheme” in the UK)
- The Solution: The UK’s MHRA allows patients and caregivers to directly report suspected ADRs through its Yellow Card Scheme website and app.
- Impact: This has significantly increased the volume and diversity of reports. Patients often report different types of reactions (e.g., quality of life impacts) than HCPs, providing a more complete safety picture. During the COVID-19 vaccine rollout, direct patient reporting was crucial for rapidly identifying rare side effects like myocarditis.
Example 3: The COVID-19 Vaccine Rollout
- The Context: The massive, global vaccination campaign led to an unprecedented number of ADR reports.
- How Underreporting Was Combated:
- Simplified Digital Platforms: Easy-to-use online portals and apps for both HCPs and the public.
- High Public Awareness: Widespread media coverage encouraged people to report any suspected side effects.
- Active Surveillance: This was used in parallel with spontaneous reporting to cross-check and validate signals (e.g., using data from large health insurance databases).
- Result: The system successfully and rapidly identified rare but serious events like vaccine-induced thrombotic thrombocytopenia (VITT) for the AstraZeneca vaccine and myocarditis for the mRNA vaccines, leading to updated usage guidelines.
In summary, underreporting is a critical weakness in drug safety systems. Overcoming it requires a shift from relying solely on voluntary, spontaneous reports to building a proactive, integrated, and participatory ecosystem where technology empowers both healthcare professionals and patients to contribute to medication safety effortlessly.
